Agenus Inc.

AGEN Healthcare Biotechnology

Agenus Inc.’s revenue for fiscal 2025 (year ended December 2025) was $114.2 million, up 10.4% from fiscal 2024. In the quarter to June 2026, revenue grew 34.4%, EPS grew 98.6%, free cash flow fell 55.3% and total debt fell 11.2%, each against the same quarter a year earlier.

6.04 0.64 −9.58%
Market cap
$301.7M
P/E
2.3×
Fwd P/E
4.1×
Dividend yield
—
F-score
4/9
Altman Z
−14.16
Beneish M
12.57
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
ROE
(33.86%) (23.40%) 0.03% 12.80%

+8 more TTM periods

Piotroski F-Score
6 5 4 2
ROA
51.30% 33.31% (0.04%) (14.98%)
ROIC
0.00% 0.00% 0.00% 0.00%
Return on Tangible Assets
(66.19%) (46.32%) 0.06% 25.79%
Average Days of Receivables
151.84 159.31 22.41 21.40
Free Cash Flow per Share
(2.37) (2.30) (2.58) (2.79)
Free Cash Flow
(98.16) (87.14) (76.84) (88.95)
Capital Expenditures
0.35 0.39 0.35 0.28
Other line items
Cash ROIC
62.50% 53.53% 33.38% 36.57%
Accounts Receivable Turnover
4.75 4.55 30.79 33.02
Accounts Payable Turnover
0.00 0.00 0.01 0.02
Inventory Turnover
— — 0.00 0.00
Average Days of Payables
0.00 0.00 29,638.21 27,307.44
Days of Inventory on Hand
— — 0.00 0.00
Tax Rate
0.00 0.00 0.00 0.00
Research and Development Expense of Revenue
43.47% 56.22% 69.48% 98.85%
Selling, General and Administrative Expense of Revenue
29.00% 36.76% 47.63% 59.00%
Share Based Compensation of Revenue
8.60% 9.19% 12.06% 14.03%
Interest Coverage
0.61 0.14 (0.36) (1.01)
Operating CF/Net income
(1.07) (1.36) 764.31 2.52
Depreciation/Fixed assets
0.33 0.49 0.65 0.79
Capex/Depreciation
0.07 0.05 0.04 0.02
Revenue per Share
3.21 3.26 3.84 3.35
Operating CF per Share
(2.38) (2.31) (2.60) (2.80)
Capex per Share
0.01 0.01 0.01 0.01
Capex to Sales
0.00 0.00 0.00 0.00

Fold the line items

Columns are period end dates